SCHEMBL16211709

SCHEMBL16211709

CCCCCCCCCCCCCCCCCCN1C(=CC=CC2=[N+](CCCCCCCCCCCCCCCCCC)c3ccccc3C2(C)C)C(C)(C)c2ccccc21

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT1 Q99873 8/20 0.73
MAPT P10636 2/20 0.62
BLM P54132 2/20 0.62
NPC1 O15118 2/20 0.62
USP2 O75604 2/20 0.62
RAB9A P51151 2/20 0.62
MEN1 O00255 1/20 0.62
S1PR2 O95136 1/20 0.62
LMNA P02545 1/20 0.62
POLB P06746 1/20 0.62
ALPG P10696 1/20 0.62
THRB P10828 1/20 0.62
PKM P14618 1/20 0.62
XBP1 P17861 1/20 0.62
CRHBP P24387 1/20 0.62
HTT P42858 1/20 0.62
RECQL P46063 1/20 0.62
KMT2A Q03164 1/20 0.62
CRHR2 Q13324 1/20 0.62
SMN1; SMN2 Q16637 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12020959 1.00 PRMT1 (0.73) PRMT1MAPTBLMNPC1USP2
SCHEMBL29551581 1.00 PRMT1 (0.73) PRMT1MAPTBLMNPC1USP2
SCHEMBL29819404 1.00 PRMT1 (0.73) PRMT1MAPTBLMNPC1USP2
SCHEMBL16211708 1.00 PRMT1 (0.73) PRMT1MAPTBLMNPC1USP2
SCHEMBL12932092 1.00 PRMT1 (0.73) PRMT1MAPTBLMNPC1USP2
SCHEMBL29696603 1.00 PRMT1 (0.73) PRMT1MAPTBLMNPC1USP2
SCHEMBL29539035 1.00 PRMT1 (0.73) PRMT1MAPTBLMNPC1USP2
SCHEMBL17694077 1.00 PRMT1 (0.73) PRMT1MAPTBLMNPC1USP2
SCHEMBL903226 1.00 PRMT1 (0.73) PRMT1MAPTBLMNPC1USP2
SCHEMBL13994353 1.00 PRMT1 (0.73) PRMT1MAPTBLMNPC1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113444125-B Phosphoramidite ligand, preparation method thereof and application thereof in asymmetric carbonylation reaction 西北大学 2024-01-26 CN claimed
WO-2026087715-A1 STIMULUS-RESPONSIVE GELABLE LIQUID COMPOSITION COMPRISING VESICLES NANOMOL TECHNOLOGIES, S.L. (ES) 2026-04-30 WO disclosed
US-12605336-B2 Fusogenic liposome-coated porous silicon nanoparticles THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-04-21 US disclosed
EP-4658313-A1 HSC-SPECIFIC ANTIBODY CONJUGATED LIPID NANOPARTICLES AND USES THEREOF GENZYME CORPORATION (US) 2025-12-10 EP disclosed
US-20250064740-A1 MULTI-VESICULAR LIPID NANOPARTICLE TOLEROGENIC VACCINES FOR INDUCTION OF SYSTEMIC IMMUNE TOLERANCE IN VIVO KARMA BIOTECHNOLOGIES (US) 2025-02-27 US disclosed
EP-2687223-B2 Detecting and treating dementia MAYO FOUND MEDICAL EDUCATION & RES (US) 2024-11-20 EP disclosed
EP-3316850-B1 FUSOGENIC LIPOSOME-COATED POROUS SILICON NANOPARTICLES UNIV CALIFORNIA (US) 2024-09-11 EP disclosed
WO-2024163905-A1 HSC-SPECIFIC ANTIBODY CONJUGATED LIPID NANOPARTICLES AND USES THEREOF GENZYME CORPORATION (US) 2024-08-08 WO disclosed
EP-4346901-A1 MRNA DELIVERY USING LIPID NANOPARTICLES The University of British Columbia (CA) 2024-04-10 EP disclosed
EP-4326239-A1 EXTRACELLULAR VESICLES LOADED WITH BIOMOLECULES Spot Biosystems Ltd. (US) 2024-02-28 EP disclosed
US-10702474-B2 Fusogenic liposome-coated porous silicon nanoparticles THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-07-07 US disclosed
EP-3524686-A1 METHOD FOR DETECTING ANTIBIOTIC-RESISTANT CELLS USING GENETIC ENGINEERED TRANSDUCTION PARTICLES Geneweave Biosciences Inc. (US) 2019-08-14 EP disclosed
EP-3134722-B1 REAGENT CARTRIDGE GENEWEAVE BIOSCIENCES INC (US) 2019-02-20 EP disclosed
US-10125386-B2 Reagent cartridge and methods for detection of cells GeneWeave Biosciences, Inc. (US) 2018-11-13 US disclosed
US-20180193268-A1 FUSOGENIC LIPOSOME-COATED POROUS SILICON NANOPARTICLES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2018-07-12 US disclosed
US-20180153984-A1 ADJUVANT PARTICLES COMPRISING ADENOSINE RECEPTOR ANTAGONISTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-07 US disclosed
US-20170233783-A1 REAGENT CARTRIDGE AND METHODS FOR DETECTION OF CELLS GeneWeave Biosciences, Inc. (US) 2017-08-17 US disclosed
US-9540675-B2 Reagent cartridge and methods for detection of cells GeneWeave Biosciences, Inc. (US) 2017-01-10 US disclosed
US-20150218613-A1 REAGENT CARTRIDGE AND METHODS FOR DETECTION OF CELLS GeneWeave Biosciences, Inc. (US) 2015-08-06 US disclosed
WO-2014176934-A1 USE OF TRADITIONAL CHINESE MEDICINE COMPOSITION IN PREPARATION OF DRUGS FOR TREATING OR PREVENTING ANGIOGENESIS RELATED DISEASES 河北以岭医药研究院有限公司 (CN) 2014-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12605336-B2 Fusogenic liposome-coated porous silicon nanoparticles NSF, FUS, STIM1 PRMT1 3856/4885MAPT 1246/4885BLM 4407/4885
US-20180193268-A1 FUSOGENIC LIPOSOME-COATED POROUS SILICON NANOPARTICLES FUS, NSF, SELPLG PRMT1 3694/4885MAPT 2442/4885BLM 3517/4885
US-10702474-B2 Fusogenic liposome-coated porous silicon nanoparticles FUS, NSF, SELPLG PRMT1 3694/4885MAPT 2442/4885BLM 3517/4885
US-20250064740-A1 MULTI-VESICULAR LIPID NANOPARTICLE TOLEROGENIC VACCINES FOR INDUCTION OF SYSTEMIC IMMUNE TOLERANCE IN VIVO PLTP, CD47, PHOSPHO1 PRMT1 4117/4885MAPT 2489/4885BLM 642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.